

Company Profile

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Executive Board



Thomas Meier,
CEO



Falk Neukirch,
CFO




Christoph Pruseit,
CBO¹ Germany




Constantijn van Rietschoten,
CBO¹ International


Structure and Segments




FY² 2024 EBITDA pre³ split⁴



Consolidated Revenue in €m



Consolidated EBITDA pre³ in €m



¹ CBO = Chief Business Officer, ² Full Year; ³ adjusted for extraordinary expenses (EBITDA pre); ⁴ Including the segment "Services" (-13% in FY 2024); ⁵ CAGR = Compound Annual Growth Rate; *adjusted for extraordinary expenses

Contact:
ir@medios.group
www.medios.group

Key Figures

in €m	2024 (IFRS)	2023 (IFRS)	Change
Revenue	1,883.0	1,784.7	+5.5%
EBITDA pre*	79.0	60.5	+30.5%
Margin in %	4.2	3.4	+23.5%

*adjusted for extraordinary expenses

Basic Information

Share Capital	€25,505,723
No. of shares	25,505,723
Share class	No-par value bearer shares
WKN / ISIN	A1MMCC / DE000A1MMCC8
Trading places	Regulated Market Frankfurt (Prime Standard), SDAX


Shareholder Structure

All figures according to voting rights notifications of the notifying parties

65.2%

Free float¹

- 6.4% Janus Henderson
- 6.1% Axxion
- 4.7% SEB Investment
- 3.9% Treasury Shares²
- 2.4% Paladin Asset Management



19.7%

Martin Hesse³

incl. attribution of BMSH GmbH

15.1%

Luxempart Invest S.á.r.l.

¹ Free Float as defined by Deutsche Börse Group

² Treasury shares from the share buy-back offer do not carry voting or dividend rights (treasury shares as of July 17, 2025: 1,000,000 shares)

³ Incl. attribution of BMSH GmbH

Share Price in €

